Tissue Regenix Group PLC (AIM:TRX) has said it still cannot provide certainty over its financial position before its planned delisting on 7 January, leaving its shares suspended until the cancellation takes effect.
The company said it expects to stay solvent if shareholders approve resolutions at a meeting on 22 December and if £7.5 million is drawn from a secured convertible loan shortly afterwards.
But financial pressures and unclear trading meant the board could not update investors further. A matched bargain facility will allow trading from the delisting date for at least a year.